Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma

(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.